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Recently, the Prospective comparison of ARni (Angiotensin receptor-neprilysin inhibitor) 
with Arb (angiotensin receptor blocker) Global Outcomes in heart failure (HF) with 
preserved ejectioN fraction trial (PARAGON-HF) suggested that women might obtain more 
benefit than men from sacubitril/valsartan, compared with valsartan, in HF with preserved 
ejection fraction (HFpEF).1–3 However, the picture is more complicated as there was also an 
interaction between left ventricular ejection fraction (LVEF) and the effect of 
sacubitril/valsartan.2 Patients with a LVEF at or below the median (57%) seemed to gain 
more benefit from than sacubitril/valsartan those with a LVEF above the median.2 To make 
matters more complex still, it is well known that the distribution of LVEF is different in 
women and men, with women, on average, having a higher LVEF than men, be it in the 
general population or in individuals with heart failure.4-6  Despite a higher LVEF, women with 
HFpEF had worse systolic function, as assessed by tissue Doppler echocardiography, 
compared to men with HFpEF.7 To further investigate the relationship between sex, LVEF 
and treatment in HF, we explored the effect of three different neurohumoral modulators in 
large trials which provide data on clinical outcomes in patients with HF, across the full range 
This article is protected by copyright. All rights reserved.
4 
 
of LVEF, incorporating the three commonly described HF phenotypes – HF with reduced 
ejection fraction (HFrEF - LVEF <40%), HF with preserved ejection fraction (HFpEF – LVEF 
>50%) and HF with mid-range ejection fraction (HFmrEF - LVEF 40-50%).8 
We pooled individual patient-level data from: 1) Three trials using an angiotensin receptor 
blocker - The Candesartan in Heart failure: Assessment of Reduction in Mortality and 
morbidity (CHARM) – the CHARM-Alternative and CHARM-Added trials in HFrEF and the 
CHARM-Preserved trial in HFmrEF/HFpEF.9 2) Three trials using a mineralocorticoid receptor 
antagonist (MRAs) – two HFrEF trials, the Randomised Aldactone Evaluation Study (RALES), 
Eplerenone in Mild Patients Hospitalization and Survival Study in HF trial (EMPHASIS-HF) and 
one HFmrEF/HFpEF trial - the Treatment of Preserved Cardiac Function Heart Failure with an 
Aldosterone Antagonist trial (TOPCAT).10–12 Only TOPCAT patients from the Americas were 
included. 3) Two trials using sacubitril-valsartan – the Prospective Comparison of ARNI with 
ACEI to Determine Impact on Global Mortality and Morbidity in HF trial (PARADIGM-HF) in 
HFrEF and PARAGON-HF in HFmrEF/HFpEF.1,13  
Cox proportional hazards modelling was used to analyse i) the primary composite outcome 
(first occurrence of HF hospitalization or cardiovascular death), ii) first HF hospitalization 
and iii) cardiovascular death. Likelihood ratio tests were used to report i) two-way 
interactions between treatment and sex and ii) three-way interaction between treatment, 
sex and LVEF. LVEF, modelled as a fractional polynomial, and its interaction with treatment 
using the best fit model for each drug category (based on the primary composite outcome) 
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was examined with the mfpi command in Stata. Models were stratified by trial for MRAs and 
sacubitril-valsartan. All analyses were conducted using Stata ver.16.  
This present analysis included 2400, 1938 and 4311 women and 5199, 4229 and 8884 men 
in the candesartan, MRA and sacubitril-valsartan trials, respectively [Table 1]. Overall mean 
LVEF (%) was 38.9±14.9, 35.3±16.0 and 39.7±15.1, respectively. Women had a higher mean 
LVEF, with the difference compared to men 6.3%, 9.4% and 10.3%, respectively. Women 
had a lower incidence of the primary composite outcome (and its components) in each of 
the treatment and control groups.  
In keeping with prior reports from the CHARM Program and TOPCAT, as well as a recent 
analysis of PARADIGM-HF and PARAGON-HF, we found that that treatment with an ARB , 
MRA or ARNI may be of benefit beyond the upper limit of LVEF eligibility used in 
contemporary HFrEF clinical trials (40%) and may extend to what has been termed HFmrEF 
(LVEF 40-49%) and even to the lower part of the LVEF range currently categorized as 
HFpEF.2,6,14,15   Importantly, the benefit of each treatment seemed to extend to a higher 
LVEF in women, compared to men [Figure 1]. There was no difference in efficacy of therapy 
between men and women with HFrEF. 
Because these are post hoc analyses, they are only hypothesis generating. However, the fact 
that all three neurohumoral modulating therapies demonstrated the same sex-related 
pattern of response raises the possibility that the differential response between women and 
men identified in PARAGON-HF may be real rather than due to the play of chance, although 
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interpretation of PARAGON-HF is more complex as it had an active comparator compared 
with a placebo control in the other trials. Despite this consistent observation in the trials 
examined, the biological basis for such a finding is uncertain. As detailed elsewhere, the 
possibilities include sex-related differences in cardiac remodelling in response to blood 
pressure, age and other stimuli, and differences in age-related arterial stiffening, which is 
more pronounced in women than men.3 Women may also have other evidence of 
contractile dysfunction, compared with men, for a given ejection fraction.3 Natriuretic 
peptide levels are lower in women with HFpEF, than in men and women may have reduced 
cyclic guanosine monophosphate (cGMP)-protein kinase G (PKG) signalling compared with 
men, especially after the menopause.3 The possibility that women with HF might benefit 
from treatment to a higher level of LVEF than previously considered could be of great 
clinical importance. Women with HF have fewer treatment options than men with HF 
because HFmrEF and HFpEF are the predominant HF phenotypes in women and no therapy 
has been approved by regulatory authorities for either of these phenotypes.6 More research 
on this matter is clearly required. 
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Table 1: Interaction of treatment and left ventricular ejection fraction in men and women with heart failure.    
 Overall Men Women p-interaction* p-interaction$ p-interaction# 
Candesartan       
Number of patients 7599 5199 2400    
Age – mean ± SD 65.5 ± 11.1 64.4 ± 10.9 67.8 ± 11.1    
Ejection fraction – mean ± SD 38.9 ± 14.9 36.9 ± 14.0    43.2 ± 15.8    
Primary composite outcome       
Event rate per 
100 pt. yrs. (95% CI)   Placebo 13.8 (13.1 – 14.6) 14.3 (13.4 – 15.2) 12.9 (11.7 – 14.3)    
                                       Candesartan 11.6 (10.9 – 12.2)   11.9 (11.1 – 12.7) 10.8 (9.7 – 12.0)    
Hazard ratio (95% CI)  0.84 (0.78 – 0.91) <0.001 0.84 (0.76 – 0.92) 0.84 (0.73 – 0.97) 0.9939 0.0146 0.0649 
HF hospitalization       
Event rate per 
100 pt. yrs. (95% CI)   Placebo 9.7 (9.1 – 10.3) 9.7 (9.0 – 10.5) 9.6 (8.6 – 10.8)    
                                       Candesartan 7.6 (7.1 – 8.2) 7.6 (7.0 – 8.3) 7.5 (6.6 – 8.6)    
Hazard ratio (95% CI)  0.79 (0.72 – 0.87) <0.001 0.79 (0.70 – 0.89) 0.79 (0.66 – 0.94) 0.9824 0.0566 0.1361 
Cardiovascular death       
Event rate per 
100 pt. yrs. (95% CI)   Placebo 7.2 (6.7 – 7.7) 7.6 (7.0 – 8.3) 6.3 (5.5 – 7.2)    
                                       Candesartan 6.3 (5.9 – 6.8) 6.7 (6.2 – 7.4) 5.4 (4.7 – 6.2)    
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Hazard ratio (95% CI)  0.88 (0.79 – 0.97) 0.013 0.89 (0.79 – 1.00) 0.86 (0.70 – 1.04) 0.7531 0.3454 0.1876 
Mineralocorticoid receptor blocker 
(MRA)       
Number of patients 6167 4229 1938    
Age – mean ± SD 68.5 ± 9.8 67.8 ± 9.6 70.1 ± 10.1    
Ejection fraction – mean ± SD 35.3 ± 16.0 32.3 ± 14.0 41.7 ± 18.1    
Primary outcome       
Event rate per 
100 pt. yrs. (95% CI)   Placebo 20.0 (18.8 – 21.2) 21.7 (20.2 – 23.3) 16.8 (15.0 – 18.7)    
                                       MRA 14.0 (13.1 – 15.0) 15.2 (14.0 – 16.4) 11.8 (10.5 – 13.4)    
Hazard ratio (95% CI)  0.70 (0.64 – 0.77) <0.001 0.70 (0.63 – 0.77) 0.71 (0.60 – 0.84) 0.8089 0.0074 0.0682 
HF hospitalization       
Event rate per 
100 pt. yrs. (95% CI)   Placebo 13.9 (13.0 – 14.9) 14.8 (13.5 – 16.1) 12.3 (10.9 – 14.0)    
                                       MRA 9.4 (8.7 – 10.2)   9.9 (9.0 – 11.0) 8.4 (7.3 – 9.8)    
Hazard ratio (95% CI)  0.69 (0.62 – 0.77) <0.001 0.68 (0.60 – 0.78) 0.70 (0.57 – 0.85) 0.8567 0.0077 0.1006 
Cardiovascular death        
Event rate per 
100 pt. yrs. (95% CI)   Placebo 9.7 (9.0 – 10.5) 10.8 (9.8 – 11.8) 7.6 (6.6 – 8.9)    
                                       MRA 7.0 (6.4 – 7.7)   8.1 (7.3 – 9.0) 5.1 (4.2 – 6.1)    
Hazard ratio (95% CI) 0.73 (0.65 – 0.82) <0.001 0.75 (0.65 – 0.86) 0.67 (0.53 – 0.84) 0.4100 0.9333 0.9494 
This article is protected by copyright. All rights reserved.
14 
 
Sacubitril-valsartan       
Number of patients 13195 8884 4311    
Age – mean ± SD 67.0 ± 11.3 65.6 ± 11.3 70.0 ± 10.6    
Ejection fraction – mean ± SD 39.7 ± 15.1 36.3 ± 13.4 46.6 ± 16.0    
Primary outcome       
Event rate per 
100 pt. yrs. (95% CI)   RAAS inhibitor 11.4 (10.8 – 11.9) 12.3 (11.6 – 13.0) 9.6 (8.8 – 10.5)    
                                       Sacubitril-valsartan 9.5 (9.1 – 10.0) 10.6 (9.9 – 11.2) 7.6 (6.9 – 8.4)    
Hazard ratio (95% CI)  0.84 (0.78 – 0.90) <0.001 0.86 (0.79 – 0.93) 0.79 (0.70 – 0.91) 0.3452 0.0424 0.0034 
HF hospitalization       
Event rate per 
100 pt. yrs. (95% CI)   RAAS inhibitor 7.4 (7.0 – 7.9) 7.6 (7.1 – 8.2)   7.0 (6.3 – 7.8)    
                                       Sacubitril-valsartan 6.2 (5.9 – 6.6) 6.7 (6.2 – 7.3) 5.3 (4.7 – 5.9)    
Hazard ratio (95% CI)  0.84 (0.77 – 0.92) <0.001 0.89 (0.80 – 0.98) 0.76 (0.65 – 0.88) 0.1003 0.0560 0.0057 
Cardiovascular death       
Event rate per 
100 pt. yrs. (95% CI)   RAAS inhibitor 5.6 (5.3 – 6.0)   6.6 (6.1 – 7.1) 3.8 (3.3 – 4.3)    
                                       Sacubitril-valsartan   4.7 (4.4 – 5.0)   5.4 (5.0 – 5.9) 3.3 (2.9 – 3.8)    
Hazard ratio (95% CI)  0.83 (0.76 – 0.92) <0.001 0.81 (0.73 – 0.91) 0.89 (0.73 – 1.08) 0.4461 0.2136 0.5871 
*Interaction between treatment and sex. 
$Interaction between treatment and ejection fraction modelled as a fractional polynomial.  
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#Three-way interaction between treatment, sex and ejection fraction. 
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            Figure legend 
Figure 1: Variation of treatment effect with left ventricular ejection fraction in heart 
failure.  
Dotted curves show normalized distribution of LVEF in men (blue) and women (red). Solid 
blue (men) and red (women) lines show a continuous hazard ratio for the primary 
composite and its components, according to treatment group the range of LVEF included. 
The shaded areas represent the 95% confidence intervals:  
Primary outcome (HF hospitalization/cardiovascular death) 
A) candesartan vs placebo 
B) MRA vs placebo  
C) sacubitril-valsartan vs RAAS inhibitor. 
Heart failure hospitalization 
D) candesartan vs placebo 
E) MRA vs placebo  
F) sacubitril-valsartan vs RAAS inhibitor 
Cardiovascular death 
G) candesartan vs placebo 
H) MRA vs placebo  
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I) sacubitril-valsartan vs RAAS inhibitor    
This article is protected by copyright. All rights reserved.











20 30 40 50 60 70
Ejection fraction (%)















This article is protected by copyright. All rights reserved.











20 30 40 50 60 70
Ejection fraction (%)















This article is protected by copyright. All rights reserved.











20 30 40 50 60 70
Ejection fraction (%)















This article is protected by copyright. All rights reserved.











20 30 40 50 60 70
Ejection fraction (%)















This article is protected by copyright. All rights reserved.











20 30 40 50 60 70
Ejection fraction (%)















This article is protected by copyright. All rights reserved.











20 30 40 50 60 70
Ejection fraction (%)















This article is protected by copyright. All rights reserved.











20 30 40 50 60 70
Ejection fraction (%)















This article is protected by copyright. All rights reserved.











20 30 40 50 60 70
Ejection fraction (%)















This article is protected by copyright. All rights reserved.











20 30 40 50 60 70
Ejection fraction (%)















This article is protected by copyright. All rights reserved.
